NCT01191580 is a Phase 4 clinical trial of Interpersonal Psychotherapy in Major Depression, sponsored by New York State Psychiatric Institute.

Who is sponsoring NCT01191580?

NCT01191580 is sponsored by New York State Psychiatric Institute.

What drugs are being tested in NCT01191580?

Interventions in NCT01191580: Interpersonal Psychotherapy, Problem-Solving Therapy, Brief Supportive Psychotherapy.

What condition does NCT01191580 study?

NCT01191580 studies Major Depression.

Is NCT01191580 still recruiting?

NCT01191580 is currently completed. Last updated 13 July 2017.

Last reviewed 2017-07-13 · How we verify

NCT01191580

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interpersonal Therapy for Depression in Breast Cancer

Completed Phase 4 Last updated 13 July 2017

What this trial tests

Phase 4 trial testing Interpersonal Psychotherapy in Major Depression in 134 participants. Completed in 1 June 2017.

Timeline

1 October 2009

Primary endpoint
1 April 2016

1 June 2017

Quick facts

Lead sponsor	New York State Psychiatric Institute
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	134
Start date	1 October 2009
Primary completion	1 April 2016
Estimated completion	1 June 2017
Sites	1 location across United States

Drugs / interventions tested

Interpersonal Psychotherapy
Problem-Solving Therapy
Brief Supportive Psychotherapy

Conditions studied

Major Depression — all drugs for Major Depression →

Sponsor

New York State Psychiatric Institute

Who can join

Adults 18 to 90, any sex, with Major Depression. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Hamilton Depression Scale (HAMD-17)
Time frame: week 12
Change in HAMD-17 following acute treatment is the primary outcome measure

Sponsor's own description

The investigators propose a randomized clinical trial to compare the efficacy of Interpersonal Psychotherapy (IPT), Problem-Solving Therapy (PST), and Brief Supportive Psychotherapy (BSP), in improving depressive symptoms, psychosocial functioning, and quality of life among patients with breast cancer and major depressive disorder (MDD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Interpersonal Psychotherapy

Trials testing the same drug.

NCT06014671 — The Effect of Interpersonal Psychotherapy on Quality of Life Among People Living With HIVAIDS · NA · completed
NCT04973930 — Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer · Phase 3 · suspended
NCT06056453 — Interpersonal Psychotherapy in Adolescents With Polycystic Ovary Syndrome · NA · completed
NCT03466346 — SMART-DAPPER: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research Project · NA · completed
NCT03594773 — Modeling Multi-level Dyadic Behavior to Transform the Science and Practice of Psychotherapy Process and Outcome. · NA · completed

Other recruiting trials for Major Depression

Currently open trials in the same condition.

NCT07031817 — Validation of a Composite Medical Device Using a Blood Biomarker-based Algorithm and MDQ for the Diagnosis of Bipolar Di · NA · recruiting
NCT07184697 — Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD. · NA · active not recruiting
NCT07463911 — Treatment Response In ECT Patients · active not recruiting
NCT06763081 — Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation · recruiting
NCT06781593 — Combining Light Therapy and CPAP in Depression · NA · recruiting

Other New York State Psychiatric Institute trials

Trials by the same sponsor.

NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01191580 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
Last refreshed: 13 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01191580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing